Document is current
Any future updates will be listed below
-
Authors
Chou, David B. https://orcid.org/0000-0002-1659-9308
Furlong, Brooke A. https://orcid.org/0000-0001-7584-0707
Posey, Ryan R.
Kyprianou, Christos https://orcid.org/0000-0001-8516-9195
O’Sullivan, Lucy R.
David, Rhiannon
Randle, Suzanne J.
Polanska, Urszula M.
Travers, Jon
Urosevic, Jelena
Hutchinson, John N.
Che, Jianwei
Howley, Anna M.
Hasserjian, Robert P.
Prantil-Baun, Rachelle
Ingber, Donald E. https://orcid.org/0000-0002-4319-6520
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | U.S. Food and Drug Administration (HHSF223201310079C)
- License Information
-
More Information
Article History
Received: 25 October 2021
Accepted: 21 September 2022
First Online: 12 October 2022
Competing interests
: R.D., S.J.R., U.M.P., and J.U. are employed by AstraZeneca, which is developing nanoparticle-encapsulated AZD2811. J.C. is a consultant and equity holder to Soltego, Allorion, Matchpoint, and scientific cofounder for Matchpoint, M3 bioinformatics & technology Inc. The remaining authors declare no competing interests.
